We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
LENVIMA (Eisai Australia Pty Ltd)
Product name
LENVIMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
lenvatinib mesilate
Registration type
EOI
Indication
LENVIMA (hard capsule), in combination with pembrolizumab, is now also indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).